655 results about "Granulocytic cells" patented technology

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

The invention discloses a monoclonal antibody which only specifically recognizes neutrophil apolipoprotein homodimer HNL / HNL and does not recognize monomer form HNL. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The monoclonal antibody realizes accurate, simple and rapid quantification of homodimer form HNL / HNL, promotes wide clinical application of the detection index, accurately distinguishes bacterial infection and virus infection, and reduces unreasonable use of antibiotics.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating sepsis-related acute lung injury and application thereof. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients in parts by mass: 5-15 parts of cassia twig, 5-15 parts of rheum officinale, 10-20 parts of peach kernel, 25-35 parts of gypsum and 10-20 parts of kudzu vine root. Animal experiments show that the traditional Chinese medicine composition can effectively improve lung tissue pathological manifestations of mice with sepsis-related acute lung injury by inhibiting polarization of M1 type macrophages, promoting polarization of M2 type macrophages, improving the infiltration level of neutrophils and inhibiting release of inflammatory factors. Therefore, the traditional Chinese medicine composition disclosed by the invention has a good treatment effect on acute lung injury related to sepsis.

The invention relates to the technical field of medical treatment, and particularly discloses a compound prognosis model for cancer prognosis evaluation, a prognosis evaluation method and a calculator. The compound prognosis model is constructed based on inflammation burden related prognosis indexes ALNCR and TNM by stage combination; the creation method comprises the following steps: step 1, collecting albumin concentration, lymphocyte count, neutrophil count and C-reactive protein concentration data of a cancer patient; 2, calculating an ALNCR index according to a formula; 3, according to a clinical classic TNM staging system, the patients are divided into a TNM staging stage I, a TNM staging stage II, a TNM staging stage III or a TNM staging stage IV; 4, the ALNCR index obtained in the step 2 and the TNM staging result obtained in the step 3 are associated and integrated, and the individualized prognosis score of the ALNCR.TNM composite prognosis model is obtained through calculation. The method is suitable for clinical rapid application; high-risk patients can be accurately distinguished, a quantitative basis is provided for individualized treatment and follow-up visit strategy formulation, and excessive medical treatment or insufficient treatment is reduced.

Described herein are methods of managing eosinophilic esophagitis (EoE) in a patient, wherein the patient records the number of episodes of dysphagia on a patient report outcome (PRO) questionnaire prior to and during the course of treatment. While on treatment, the number of episodes of dysphagia are reduced, as reported on the PRO questionnaire. In some embodiments, the esophageal eosinophils are counted before or after treatment, or both. In some embodiments, esophageal eosinophils counts are not correlated with a reduction in the episodes of dysphagia.

The invention belongs to the technical field of biological medicines, and particularly discloses a bionic nano-vesicle for regulating and controlling neutrophil phenotype in combination with ultrasound, and a preparation method and application of the bionic nano-vesicle. The bionic nano-vesicle provided by the invention can be broken under the action of high-concentration glutathione existing in a tumor tissue microenvironment to release the sound-sensitive agent and functional siRNA, and under the action of US irradiation, the sound-sensitive agent is activated to generate a large amount of ROS, promote tumor cell DNA breakage, generate a large amount of double-stranded DNA, activate APC and promote IFN-beta release, so that the tumor tissue microenvironment is inhibited. The released functional siRNA can promote the N2-type neutrophile granulocyte to become N1-type neutrophile granulocyte, and the released functional siRNA can prevent the N1-type neutrophile granulocyte from being reversed to the N2-type neutrophile granulocyte again, so that the regulation and control on the phenotype of the neutrophile granulocyte are realized; under catalysis of CAT rich in the thylakoid membrane, H2O2 overexpressed by tumor tissue is decomposed into oxygen, the tumor hypoxia microenvironment can be relieved, and the tumor treatment effect can be improved.

The present invention relates to an anti-neutrophil elastase (NE) antibody or antigen-binding fragment thereof that specifically binds to NE, wherein the anti-NE antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) including a heavy chain CDR1 represented by the amino acid sequence of SEQ ID NO: 1, 7, or 13, a heavy chain CDR2 represented by the amino acid sequence of SEQ ID NO: 2, 8, or 14, and a heavy chain CDR3 represented by the amino acid sequence of SEQ ID NO: 3, 9, or 15; and a light chain variable region (VL) including a light chain CDR1 represented by the amino acid sequence of SEQ ID NO: 4, 10, or 16, a light chain CDR2 represented by the amino acid sequence of SEQ ID NO: 5, 11, or 17, and a light chain CDR3 represented by the amino acid sequence of SEQ ID NO: 6, 12, or 18. The antibody of the present invention exhibits excellent NE neutralizing activity, and thus can be used for preventing or treating NE hyperactivation-related diseases.

The invention discloses a functional hydrogel microsphere and a preparation method and application thereof, and relates to the technical field of medicines.The preparation method comprises the steps that a hyaluronic acid methacrylic acid precursor solution and an IL-1beta shRNA adenovirus stock solution are mixed to obtain an Ad-atHAMA precursor solution; preparing the Ad (at) HAMA precursor solution through an oil-in-water micro-fluidic technology to obtain an Ad (at) HAMA microsphere; and sequentially adding the Ad (at) HAMA microspheres, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide into a 2-morpholinoethanesulfonic acid buffer solution, carrying out activating treatment, adding E selectin, and incubating to obtain the functionalized hydrogel microspheres. The functionalized hydrogel microspheres can inhibit a related mechanism of acute spinal cord injury pathological progress and promote neural function repair by targeting adsorption of neutrophil to regulate Nets-triggered innate immune inflammation cascade.

The invention discloses a multichannel tissue-derived neutrophil detection chip and an application system, the chip is a multichannel detection chip integrating migration-related markers and functional markers, rapid and synchronous identification of neutrophil tissue sources is realized, the migration-related markers are CD62L and CXCR4, the functional markers are CD44 and MPO, and the migration-related markers are CD62L and CXCR4. According to the method, migration related markers and functional state markers are subjected to integrated and collaborative analysis, tissue sources are locked from the cell state and function two dimensions, four-channel parallel detection is performed, and the tissue sources of the neutrophil are accurately judged through expression profile modes of the four components instead of a single marker, so that the neutrophil detection accuracy is improved. According to the method, the neutrophil tissue source is rapidly, synchronously and accurately identified, the technical bottleneck of neutrophil tissue source detection is broken through, high efficiency, accuracy and universality are achieved, and an efficient and accurate tool is provided for immune mechanism research and clinical diagnosis.

The invention provides a method for inducing HL-60 cells to be differentiated into neutrophil-like cells, and belongs to the technical field of cell culture. According to the method, the induced differentiation efficiency of the HL-60 cells to the neutrophil-like cells (D-HL-60) and the cell quality are remarkably improved, high-proportion functional D-HL-60 cells can be obtained, a good motility rate can be maintained, and a stable and reliable cell model is provided for researching a neutrophil differentiation mechanism, screening related drugs and analyzing immune functions. Particularly, the functional D-HL-60 cells obtained on the basis of the method can be used as an ideal model, deep analysis of neutrophil trapping nets (NETs) in inflammation and tumor pathological mechanisms is assisted, and an experimental basis is provided for development of therapeutic strategies of targeted NETs.

Provided herein are methods for coating a microparticle, cell, or therapeutic agent with a biomimetic zona pellucida (BZP). Also provided herein are BZP-coated cells prepared using the enclosed methods. The methods for using the BZP-coated microparticle to treat diabetes are also provided.

The application discloses a cell detection method and system based on deep learning and machine vision, which comprises the following steps: cutting a cervical liquid-based cell pathology digital image into a plurality of sub-images to form a sub-image set; inputting the sub-image set into a normal cell detection model and a lesion cell detection model respectively, and identifying normal cells and lesion cells and their categories; selecting an overlapping area of the normal cells and the lesion cells, and performing secondary classification on the overlapping area through a classification model; performing threshold segmentation on granulocytes in the cervical liquid-based cell pathology digital image to obtain all possible granulocyte targets, filtering to determine final granulocyte targets, and counting and determining the number of the granulocytes. The application solves the problem that the detection model in the prior art has poor detection effect due to the imbalance of normal cell and lesion cell categories, improves the accuracy of cell identification, and realizes accurate detection and identification of cervical liquid-based cells in combination with accurately identified granulocytes.

Methods for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3 are disclosed, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to such a cancer patient, effective to reduce the patient's NLR. The methods include administering a nonsteroidal GRA and a cancer treatment to such a cancer patient, effective to reduce the patient's NLR and enhance the treatment of the cancer patient. The GRA may be orally administered. The nonsteroidal GRA may be a nonsteroidal compound comprising a heteroaryl ketone fused azadecalin structure (e.g., relacorilant) or an octahydro fused azadecalin structure (e.g., exicorilant). The cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery. The methods may enhance the cancer treatment, improve the prognosis of the cancer patient, improve the survival of the cancer patient, and provide beneficial clinical effects and advantages to the patient.

The application discloses a kind of neutrophil membrane fusion liposome biomimetic nanomedicine carrier and its preparation method and application, belong to medical field.The carrier includes liposome and the neutrophil membrane fused to liposome;Liposome raw materials include DOPE, DPPC and cholesterol, and mass ratio is 6:3:1 in turn;Liposome and membrane protein mass ratio is 1:1.The application establishes quantitative analysis strategy based on NanoFCM, can accurately evaluate the fusion efficiency and fusion uniformity of NM@lipos at single particle level.Based on DOPE, the hybridization efficiency of NM@lipos (D) reaches 92.0%, which is significantly higher than that of NM@lipos (L) based on lecithin (70.1%).In in vivo experiment, the tumor enrichment capacity of NM@lipos (D) is increased by 5.1 times compared with Lipos (D) in 24 hours, and shows significantly prolonged circulation time.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for improving ovarian development and a preparation method and application thereof. The reagent for improving ovarian development is prepared by mixing the following raw materials in parts by weight: 20-30 parts of N-acetylcysteine; 5 to 10 parts of tranexamic acid; 3 to 8 parts of creatine; and 3000 parts of water. According to the reagent, the mRNA expression of PKD1P6 and follicle stimulating hormone receptors (FSHR) in ovarian tissues is up-regulated, the activity and functions of cumulus granular cells are enhanced, and apoptosis of the cumulus granular cells is inhibited, so that the effects of effectively promoting follicle development and inhibiting the apoptosis of the cumulus granular cells are achieved.

The invention relates to the technical field of biological medicine, in particular to 7-dehydrocholesterol liposome and application thereof. According to the invention, a biological membrane modified liposome is constructed, and the biological membrane modified liposome comprises an ROS responsive liposome, a neutrophile granulocyte membrane and a renal tubular epithelial cell membrane; the biofilm modified liposome has an active oxygen species (ROS) responsive release function and a dual targeting capability, has the advantages of an integrated drug effect carrier, ROS triggered release, dual bionic targeting, strong target cell uptake and multi-mechanism ferroptosis resistance, and can be used for preparing the biofilm modified liposome. The compound can be used for treating ferroptosis related diseases such as acute kidney injury, myocardial ischemia-reperfusion injury and cerebral ischemia-reperfusion injury, and has wide clinical popularization value.

Disclosed herein are engineered neutrophil extracellular vesicles comprising a cancer- or tumor cell-targeting Chimeric antigen receptor, a therapeutic composition, and at least one miRNA. Also disclosed herein are methods of reducing or inhibiting growth of a cancer or tumor by administering to a subject positive for the cancer or tumor the engineered neutrophil extracellular vesicles disclosed herein.

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

The invention discloses application of peimisine in preparation of an anti-fibrosis medicine, and belongs to the technical field of biological medicines. According to the application, mouse pulmonary interstitial fibrosis is induced through bleomycin, the treatment effect of peimine on pulmonary fibrosis is observed, and the influence of peimine on the pulmonary fibrosis process is explored. Results show that peimisine can reduce mouse lung index increase caused by bleomycin, improve damage of pulmonary alveolar structures of mice with pulmonary fibrosis, reduce aggregation of inflammatory cells, reduce serum fibrosis factors TGF-beta1 and inflammatory factors IL-2 of the mice with pulmonary fibrosis, and reduce the number of macrophages and neutrophils in BALF of the mice with pulmonary fibrosis. The peimisine has an obvious regulating effect on MRC-5 cell abnormal proliferation induced by TGF-beta1, can improve in-vivo pulmonary fibrosis induced by bleomycin by regulating the process of extracellular matrix and intercellular matrix, has an obvious treatment effect on mouse pulmonary fibrosis induced by bleomycin, is beneficial to development and utilization of peimisine, and has a good application prospect. And an effective method is provided for clinical treatment of pulmonary fibrosis.

The use of an opioid molecule, the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo [4,5-glisoquinolin-5-yl]-3H-2-benzofuran-1-one, capable of CFTR modulation and of suppressing the degranulation of basophils and mast cells, for the treatment of dry eye and eyes suffering from allergies.

The invention discloses a formyl peptide receptor 1 polypeptide blocker for resisting acute lung injury and pharmaceutical application thereof. The invention provides a polypeptide with a sequence as shown in Sequence NO.1, and the polypeptide is reported for the first time. Pharmacological activity studies show that the polypeptide shown as Sequence NO.1 can significantly improve lung tissue structure damage of acute lung injury model mice, reduce the level of proinflammatory factors and reduce neutrophil infiltration, and shows an obvious acute lung injury resisting effect. Therefore, the polypeptide as shown in the Sequence NO.1 provided by the invention has a prospect of being developed into the acute lung injury resisting medicine. Specifically, the polypeptide shown as Sequence NO.1 can be used as a unique active ingredient for preparing the medicine for treating and resisting the acute lung injury, and can also be combined with other active ingredients to form a composition for preparing the medicine for treating and resisting the acute lung injury.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

Compositions and methods for treating inflammation associated with Farber disease in a subject in need thereof by administering to the subject a pharmaceutical composition comprising a recombinant human acid ceramidase in a therapeutically effective amount of about 0.1 mg / kg to about 50 mg / kg to inhibit inflammation and / or to inhibit or reduce pro-inflammatory potential of neutrophils and / or monocytes in the subject.

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

The invention relates to the technical field of biological medicines, and discloses a blocking antibody targeting CXCL6 and an application of the blocking antibody in preparation of antitumor drugs. The antibody or antigen-binding fragment thereof is capable of binding specifically to human CXCL6 protein with high affinity (e.g., Kd < = 1 nM). According to the invention, the specificity and high affinity of the antibody are verified by Western Blot, immunofluorescence, immunohistochemistry and surface plasmon resonance (SPR) technologies. Functional experiments show that the antibody can effectively block CXCL6-induced neutrophil chemotaxis, including in Transwell, a three-dimensional gel model and a zebra fish living body model. Besides, in a mouse MC38 colon cancer model, the antibody shows remarkable anti-tumor activity and can inhibit tumor growth driven by CXCL6. The invention also provides a pharmaceutical composition containing the antibody, and application of the antibody in preparation of drugs for preventing or treating diseases (such as inflammatory diseases, autoimmune diseases and cancers) related to abnormal expression or activity of CXCL6.

The features of the present invention for providing a novel neutrophil activator are as follows. 1. An IL-8 production accelerator containing at least one selected from GlcCer[d18:2(4E,8Z) / 18:0], GlcCer[d18:2(4E,8Z) / 20:0], GlcCer[d18:2(4E,8Z) / 22:0], GlcCer[d18:2(4E,8Z) / 24:0], and GlcCer[d18:2(4E,8Z) / 26:0] as an active ingredient. 2. An IL-8 production accelerator containing GlcCer[d18:2(4E,8E) / 24:0] as an active ingredient. 3. An IL-8 production accelerator containing at least one selected from GlcCer[t18:1(8Z) / 24:0] and GlcCer[t18:1(8Z) / 26:0] as an active ingredient. 4. An IL-8 production accelerator containing GlcCer[d18:1(4E) / 20:0] as an active ingredient. 5. An IL-8 production accelerator containing at least one selected from Cer(t18:0 / 22:0), Cer(t18:0 / 23:0), Cer(t18:0 / 24:0), Cer(t18:0 / 25:0), and Cer(t18:0 / 26:0) as an active ingredient. 6. An IL-8 production accelerator containing at least one selected from Cer[t18:1(8Z) / 24:0] and Cer[d18:2(4E,8Z) / 20:0] as an active ingredient. 7. An IL-8 production accelerator containing at least one selected from Oryza Ceramide A, Oryza Ceramide B, and Oryza Ceramide C as an active ingredient.